QQ客服 官方微博 反馈留言

	PILLAR-2: PHASE 3 STUDY OF ADJUVANT EVEROLIMUS VERSUS PLACEBO IN PATIENTS WITH POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA WHO ACHIEVED COMPLETE REMISSION WITH RITUXIMAB-COMBINED CHEMOTHERAPY
	Cavalli, F.; Tobinai, K.; Rigacci, L.; Lin, T.; Ikeda, T.; Vanazzi, A.; Hino, M.; Shi, Y.; Mayer, J.; Costa, L. J.
	2016
卷号	101页码:282-282
ISSN号	0390-6078
URL标识	查看原文
收录类别	SCIE
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6383422
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Cavalli, F.,Tobinai, K.,Rigacci, L.,et al. PILLAR-2: PHASE 3 STUDY OF ADJUVANT EVEROLIMUS VERSUS PLACEBO IN PATIENTS WITH POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA WHO ACHIEVED COMPLETE REMISSION WITH RITUXIMAB-COMBINED CHEMOTHERAPY[J],2016,101:282-282.
APA	Cavalli, F..,Tobinai, K..,Rigacci, L..,Lin, T..,Ikeda, T..,...&Witzig, T. E..(2016).PILLAR-2: PHASE 3 STUDY OF ADJUVANT EVEROLIMUS VERSUS PLACEBO IN PATIENTS WITH POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA WHO ACHIEVED COMPLETE REMISSION WITH RITUXIMAB-COMBINED CHEMOTHERAPY.,101,282-282.
MLA	Cavalli, F.,et al."PILLAR-2: PHASE 3 STUDY OF ADJUVANT EVEROLIMUS VERSUS PLACEBO IN PATIENTS WITH POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA WHO ACHIEVED COMPLETE REMISSION WITH RITUXIMAB-COMBINED CHEMOTHERAPY".101(2016):282-282.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。